- Home
- RELY vs NUVL Comparison
RELY vs NUVL Comparison
Compare RELY & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELY
- NUVL
- Stock Information
- Founded
- RELY 2011
- NUVL 2017
- Country
- RELY United States
- NUVL United States
- Employees
- RELY N/A
- NUVL N/A
- Industry
- RELY Computer Software: Prepackaged Software
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- RELY Technology
- NUVL Health Care
- Exchange
- RELY Nasdaq
- NUVL Nasdaq
- Market Cap
- RELY 4.6B
- NUVL 5.4B
- IPO Year
- RELY 2021
- NUVL 2021
- Fundamental
- Price
- RELY $18.62
- NUVL $78.06
- Analyst Decision
- RELY Buy
- NUVL Strong Buy
- Analyst Count
- RELY 10
- NUVL 10
- Target Price
- RELY $27.40
- NUVL $119.60
- AVG Volume (30 Days)
- RELY 3.4M
- NUVL 544.5K
- Earning Date
- RELY 07-30-2025
- NUVL 08-07-2025
- Dividend Yield
- RELY N/A
- NUVL N/A
- EPS Growth
- RELY N/A
- NUVL N/A
- EPS
- RELY N/A
- NUVL N/A
- Revenue
- RELY $1,356,469,000.00
- NUVL N/A
- Revenue This Year
- RELY $27.85
- NUVL N/A
- Revenue Next Year
- RELY $20.42
- NUVL N/A
- P/E Ratio
- RELY N/A
- NUVL N/A
- Revenue Growth
- RELY 34.37
- NUVL N/A
- 52 Week Low
- RELY $11.92
- NUVL $55.54
- 52 Week High
- RELY $27.32
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- RELY 34.74
- NUVL 52.06
- Support Level
- RELY $18.55
- NUVL $73.66
- Resistance Level
- RELY $19.54
- NUVL $82.09
- Average True Range (ATR)
- RELY 0.71
- NUVL 2.49
- MACD
- RELY -0.14
- NUVL -0.10
- Stochastic Oscillator
- RELY 0.28
- NUVL 40.81
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.